BioSpace News Archive

Biotech Beach

US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses

A study, utilizing US Compounding’s unique drug formulation, was conducted in approximately 50 race horses.

December 7, 2017

·

4 min read

Business

Bertin and Zymo Research Announce New Collaboration

Zymo Research Corp. and Bertin announce a collaboration that ensures the sample lysis step in the microbiome workflow is complete and unbiased.

December 7, 2017

·

2 min read

Genetown

Magenta’s New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models With Combination of GROβ and Plerixafor

The study showed that GROβ was well tolerated.

December 7, 2017

·

4 min read

Resverlogix Repays $68.8M Loan

Upon repayment of the Loan, the Company has no outstanding long-term debt.

December 7, 2017

·

1 min read

Genetown

ROMIL Hi-Dry - Anhydrous Solvents You Can Depend on

ROMIL’s Hi-Dry anhydrous solvents take the high purity concept of ROMIL-SpS Super Purity Solvents one step further.

December 7, 2017

·

2 min read

Drug Development

OSE Immunotherapeutics to Resume Accrual in Phase III Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

There continue to be no safety concerns, as safety data remain similar to what was expected for Tedopi® based on the results of previous clinical trials.

December 7, 2017

·

6 min read

Biotech Bay

Scientists From SRI International and Collaborations Pharma Identify Potential New Ebola Virus Therapy

The low molecular weight immunomodulatory drug has shown promising efficacy with 100 percent survival in an Ebola virus disease model.

December 7, 2017

·

3 min read

BioCapital

RegeneRx Biopharma Releases Annual Letter to Shareholders

The letter is focused on updating shareholders on the Company’s product development and commercial partnerships, clinical trials, fund-raising, and other operational plans over the next twelve months.

December 7, 2017

·

2 min read

Pharm Country

Novartis Initiates Study Evaluating Impact of Higher Dosing of Cosentyx in Patients With Ankylosing Spondylitis

The primary endpoint of ASLeap is to determine the difference between Cosentyx 300 mg and Cosentyx 150 mg at Week 52 based on the proportion of subjects achieving inactive disease status based on the ASDAS.

December 7, 2017

·

14 min read

Business

BioPharmX Reports Third Quarter 2018 Financial Results

Total operating expenses for the third quarter of 2018 were $3.7M, compared with total operating expenses of $4.2M in the prior fiscal year’s third quarter.

December 7, 2017

·

18 min read